NCT06427460RecruitingPhase 2
Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)
Central-boost Ablative Radiation Therapy for Large Tumors or Tumors Adjacent to Organs at Risk
Source: ClinicalTrials.gov · Last updated 23 May 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In the case of large tumors or tumors closely adjacent to organs at risk, ablative doses offered by stereotactic body radiation therapy (SBRT) could not be delivered. Therefore, a technique that could provide high radiation doses to tumors without increasing of risks of severe adverse effects is required.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- First submitted
- 19 May 2024
- Start date
- 12 May 2024
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Changhai Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06427460
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 67
- From 12 May 2024 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of radiotherapy for the lesion
- History of tumor within 5 years
- Active inflammatory bowel disease in the case of pancreas or retroperitoneal tumor
- Gastrointestinal bleeding or perforation within 6 months in the case of pancreas or retroperitoneal tumor
- Infections required antibiotics
- Heart or respiratory insufficiency
Other
- ECOG ≥2 points
- Significant abnormality in blood routine test, liver and kidney function test and coagulation test
- Pregnant or breastfeeding women
Who the study is looking for
- Aged 18-75 years.
- Pathologically confirmed lung, liver, pancreas or retroperitoneal malignant tumor.
- Oligometastasis in the case of metastatic tumor
- the shortest diameter ≥2cm or the distance from the tumor to the organs at risk less than 5mm
- ECOG of 0 to 1 point
- No abnormality in blood routine test, liver and kidney function test and coagulation test (White blood cell count ≥4.0×10\^9/L, neutrophil count ≥2.0×10\^9, hemoglobin level ≥100g/L, platelet count ≥100×10\^9/L, ALT and AST level \< 2.5 times the upper limit of normal, total bilirubin and creatinine level within the normal, international normalized ratio \<2)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huojun Zhang Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.